Journal Article > ResearchFull Text
PLOS One. 17 March 2015; Volume 10 (Issue 3); DOI:10.1371/journal.pone.0120161
Avong YK, Isaakidis P, Hinderaker SG, Van der Bergh R, Ali E, et al.
PLOS One. 17 March 2015; Volume 10 (Issue 3); DOI:10.1371/journal.pone.0120161
Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria.
Journal Article > ResearchFull Text
PLOS One. 10 April 2014; Volume 9 (Issue 4); DOI:10.1371/journal.pone.0094393
Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali MA, et al.
PLOS One. 10 April 2014; Volume 9 (Issue 4); DOI:10.1371/journal.pone.0094393
Nigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them.